{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T06:49:37Z","timestamp":1776235777626,"version":"3.50.1"},"reference-count":71,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Biosimilar tumor necrosis factor inhibitors provide therapeutically equivalent alternatives to reference biologics for ankylosing spondylitis (AS) management at reduced costs. Clinical adoption depends on the confidence that switching stable patients from reference products to biosimilars maintains disease control. This review synthesizes the evidence on biosimilar switching in AS populations from regulatory approval programs, randomized controlled trials, and real-world observational studies. It is presented as a structured narrative review based on searches of PubMed, EMBASE, and the Cochrane Library, covering publications from January 2013 to March 2025. Approved biosimilars achieve molecular similarity and therapeutic equivalence to the reference products through analytical characterization, functional equivalence studies, and clinical comparability trials. Randomized switching trials demonstrate maintained efficacy and comparable safety profiles when patients with stable AS transition from the reference infliximab to biosimilar formulations. Immunogenicity profiles demonstrate equivalence between products. Multinational registry data corroborate these findings across diverse healthcare systems. Retention rates and disease activity outcomes are comparable between biosimilars and reference products when baseline patient characteristics are considered. Successful implementation requires patient engagement through transparent communication about biosimilar development and switching evidence. Individualized monitoring protocols should be tailored to baseline disease stability. Clinicians should recognize nocebo effects as a distinct contributor to switching outcomes and apply structured management strategies to address them. The accumulated evidence supports biosimilar switching as an appropriate clinical therapeutic strategy for AS patients with stable responses on reference biologics. This approach offers healthcare cost reductions without compromising treatment outcomes.<\/jats:p>","DOI":"10.3389\/fphar.2026.1803260","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:46:50Z","timestamp":1776232010000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical evidence and implementation guidance for biosimilar switching in ankylosing spondylitis"],"prefix":"10.3389","volume":"17","author":[{"given":"Luoyang","family":"Cai","sequence":"first","affiliation":[{"name":"Yunnan University of Chinese Medicine","place":["Kunming, Yunnan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[{"name":"Yunnan University of Chinese Medicine","place":["Kunming, Yunnan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangbin","family":"Fang","sequence":"additional","affiliation":[{"name":"Yunnan University of Chinese Medicine","place":["Kunming, Yunnan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[{"name":"Yunnan University of Chinese Medicine","place":["Kunming, Yunnan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Liu","sequence":"additional","affiliation":[{"name":"Yunnan University of Chinese Medicine","place":["Kunming, Yunnan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenkun","family":"Gan","sequence":"additional","affiliation":[{"name":"Yunnan University of Chinese Medicine","place":["Kunming, Yunnan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Zuo","sequence":"additional","affiliation":[{"name":"Yunnan University of Chinese Medicine","place":["Kunming, Yunnan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1758835918768419","DOI":"10.1177\/1758835918768419","article-title":"Development and 10-year history of a biosimilar: the example of binocrit\u00ae","volume":"10","author":"Aapro","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1136\/annrheumdis-2020-eular.5003","article-title":"AB0664 diagnosis delay in ankylosing spondylitis patients in Egypt: factors, socioeconomic and clinical outcome","volume":"79","author":"Abdelrahman","year":"2020","journal-title":"Ann. Rheumatic Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40259-018-0310-5","article-title":"PF-06438179\/GP1111: an infliximab biosimilar","volume":"32","author":"Al-Salama","year":"2018","journal-title":"BioDrugs"},{"key":"B4","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s13643-024-02715-w","article-title":"Efficacy, safety, and immunogenicity of biosimilars compared with the biologic etanercept in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"13","author":"Andrade","year":"2024","journal-title":"Syst. Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"5069","DOI":"10.3390\/jcm10215069","article-title":"The prevalence of cardiac diseases in a contemporary large cohort of Dutch elderly ankylosing spondylitis patients\u2014the CARDAS study","volume":"10","author":"Baniaamam","year":"2021","journal-title":"JCM"},{"key":"B6","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/annrheumdis-2016-eular.5115","article-title":"SAT0381 safety and efficacy of switching from innovator to biosimilar Infliximab in patients affected by spondyloarthritis. A 6-Month observational study","volume":"75","author":"Batticciotto","year":"2016","journal-title":"Ann. Rheumatic Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s12026-016-8843-5","article-title":"Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study","volume":"65","author":"Benucci","year":"2017","journal-title":"Immunol. Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"708168","DOI":"10.3389\/fmed.2021.708168","article-title":"Real-life retention rates and reasons for switching of biological DMARDs in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis","volume":"8","author":"Bhushan","year":"2021","journal-title":"Front. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00228-018-2418-4","article-title":"The nocebo effect challenges the non-medical infliximab switch in practice","volume":"74","author":"Boone","year":"2018","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"A546","DOI":"10.1016\/j.jval.2016.09.1155","article-title":"Clinical and economic impact of the use of infliximab biosimilar inflectra in Rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients","volume":"19","author":"Borras Blasco","year":"2016","journal-title":"Value Health"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1038\/s41591-023-02613-z","article-title":"Targeted depletion of TRBV9+ T cells as immunotherapy in a patient with ankylosing spondylitis","volume":"29","author":"Britanova","year":"2023","journal-title":"Nat. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/1744666X.2020.1858803","article-title":"Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis","volume":"17","author":"Caporali","year":"2021","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s40290-024-00541-y","article-title":"Mitigating the nocebo effect in biosimilar use and switching: a systematic review","volume":"38","author":"Car","year":"2024","journal-title":"Pharm. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00296-025-05968-3","article-title":"Scoping review of biosimilar disease-modifying antirheumatic drugs in pregnancy: evidence gaps and proposed outcome reporting framework","volume":"45","author":"Cheng","year":"2025","journal-title":"Rheumatol. Int."},{"key":"B15","doi-asserted-by":"publisher","first-page":"4366","DOI":"10.1007\/s12325-021-01834-3","article-title":"Infliximab biosimilar CT-P13 observational studies for rheumatoid arthritis, inflammatory bowel diseases, and ankylosing spondylitis: pooled analysis of long-term safety and effectiveness","volume":"38","author":"Cheon","year":"2021","journal-title":"Adv. Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1080\/03007995.2018.1441144","article-title":"Assessment of effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting for treatment of patients with active rheumatoid arthritis or ankylosing spondylitis","volume":"34","author":"Codreanu","year":"2018","journal-title":"Curr. Med. Res. Opin."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.3389\/fphar.2019.01372","article-title":"The clinical implications of nocebo effects for biosimilar therapy","volume":"10","author":"Colloca","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3390\/pharmaceutics16030321","article-title":"A regulatory perspective on biosimilar medicines","volume":"16","author":"Cordeiro","year":"2024","journal-title":"Pharmaceutics"},{"key":"B19","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s40259-017-0246-1","article-title":"GP2015: an etanercept biosimilar","volume":"31","author":"Deeks","year":"2017","journal-title":"BioDrugs"},{"key":"B20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","article-title":"Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data","volume":"21","author":"Deodhar","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","article-title":"Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study","volume":"80","author":"Deodhar","year":"2021","journal-title":"Ann. Rheumatic Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"16178","DOI":"10.1038\/s41598-020-73183-0","article-title":"Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis","volume":"10","author":"Ditto","year":"2020","journal-title":"Sci. Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1080\/03009742.2020.1732458","article-title":"Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis","volume":"49","author":"Emery","year":"2020","journal-title":"Scand. J. Rheumatology"},{"key":"B67","volume-title":"Remsima: EPAR \u2013 Public assessment report","year":"2013"},{"key":"B68","volume-title":"Erelzi: EPAR \u2013 Public assessment report","year":""},{"key":"B69","article-title":"Imraldi: EPAR \u2013 Public assessment report. EMA\/CHMP\/559383\/2017","year":""},{"key":"B70","article-title":"Zessly: CHMP summary of positive opinion. EMA\/CHMP\/58481\/2018","year":"2018"},{"key":"B71","volume-title":"Remsima SC: CHMP post-authorisation summary of positive opinion","year":"2019"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis & Rheumatology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s40259-018-0307-0","article-title":"SB5: an adalimumab biosimilar","volume":"32","author":"Frampton","year":"2018","journal-title":"BioDrugs"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1080\/13543784.2021.2010187","article-title":"Disease modification in ankylosing spondylitis with TNF inhibitors: spotlight on early phase clinical trials","volume":"30","author":"Garcia-Montoya","year":"2021","journal-title":"Expert Opin. Investigational Drugs"},{"key":"B27","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1136\/annrheumdis-2021-eular.1125","article-title":"POS0449 biologics initiation in moderate vs severe rheumatoid arthritis patients: prospective observational study from a canadian registry","volume":"80","author":"Guo","year":"2021","journal-title":"Ann. Rheumatic Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13075-024-03341-6","article-title":"Exploration of the combined role of immune checkpoints and immune cells in the diagnosis and treatment of ankylosing spondylitis: a preliminary study immune checkpoints in ankylosing spondylitis","volume":"26","author":"Huang","year":"2024","journal-title":"Arthritis Res. Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40744-019-0148-4","article-title":"Persistence, discontinuation, and switching patterns of newly initiated TNF inhibitor therapy in ankylosing spondylitis patients in the United States","volume":"6","author":"Hunter","year":"2019","journal-title":"Rheumatol. Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"956","DOI":"10.3390\/jcm8070956","article-title":"Maintained clinical remission in ankylosing spondylitis patients switched from reference infliximab to its biosimilar: an 18-Month comparative open-label study","volume":"8","author":"Kaltsonoudis","year":"2019","journal-title":"JCM"},{"key":"B31","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/acr2.11067","article-title":"Real\u2010life tolerability and effectiveness of adalimumab biosimilar in ankylosing spondylitis: the adalimumab biosimilar patient registry data","volume":"1","author":"Kapoor","year":"2019","journal-title":"ACR Open Rheumatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/annrheumdis-2017-211937","article-title":"Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases","volume":"77","author":"Kay","year":"2018","journal-title":"Ann. Rheumatic Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"267","DOI":"10.55563\/clinexprheumatol\/z0va6o","article-title":"Retention rate and long-term safety of biosimilar CT-P13 in patients with ankylosing spondylitis: data from the Korean college of rheumatology biologics registry","volume":"38","author":"Kim","year":"","journal-title":"Clin. Exp. Rheumatology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s40259-020-00432-z","article-title":"Retention rate and efficacy of the biosimilar CT-P13 versus reference infliximab in patients with ankylosing spondylitis: a propensity score\u2013matched analysis from the Korean college of rheumatology biologics registry","volume":"34","author":"Kim","year":"","journal-title":"BioDrugs"},{"key":"B35","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s40261-020-00907-5","article-title":"A 5-year retrospective analysis of drug survival, safety, and effectiveness of the infliximab biosimilar CT-P13 in patients with rheumatoid arthritis and ankylosing spondylitis","volume":"40","author":"Kim","year":"","journal-title":"Clin. Drug Investig."},{"key":"B36","doi-asserted-by":"publisher","first-page":"970","DOI":"10.3389\/fphar.2020.00970","article-title":"Uptake of biosimilar infliximab in the UK, France, Japan, and Korea: budget savings or market expansion across countries?","volume":"11","author":"Kim","year":"","journal-title":"Front. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3899\/jrheum.2024-0443","article-title":"Incidence and risk of infections in patients with radiographic axial spondyloarthritis receiving biologic therapies: a prospective observational study using the KOBIO registry","volume":"52","author":"Ko","year":"2025","journal-title":"J. Rheumatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40259-018-0306-1","article-title":"Non-pharmacological effects in switching medication: the nocebo effect in switching from originator to biosimilar agent","volume":"32","author":"Kristensen","year":"2018","journal-title":"BioDrugs"},{"key":"B39","doi-asserted-by":"publisher","first-page":"S457","DOI":"10.1016\/j.jval.2018.09.2698","article-title":"PSY123 - identification of the treatment attributes to be considered in shared decision making for ankylosing spondylitis patients: a systematic literature review","volume":"21","author":"Kwon","year":"2018","journal-title":"Value Health"},{"key":"B40","doi-asserted-by":"publisher","first-page":"5413","DOI":"10.1093\/rheumatology\/keaf313","article-title":"Effect of TNF inhibitors on the risk of cancer recurrence in patients with AS: a nested case-control study","volume":"64","author":"Kwon","year":"2025","journal-title":"Rheumatology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1136\/annrheumdis-2019-216362","article-title":"Incidence of inflammatory bowel disease in patients with ankylosing spondylitis","volume":"80","author":"Lai","year":"2021","journal-title":"Ann. Rheumatic Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1016\/j.mayocp.2020.06.039","article-title":"Clinical development times for biosimilars in the United States","volume":"95","author":"Lee","year":"2020","journal-title":"Mayo Clin. Proc."},{"key":"B43","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.3390\/jcm10194568","article-title":"Impact of infliximab biosimilar CT-P13 dose and infusion interval on real-world drug survival and effectiveness in patients with ankylosing spondylitis","volume":"10","author":"Lee","year":"2021","journal-title":"JCM"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.3390\/biomedicines13092089","article-title":"Association between adalimumab dosing interval and uveitis recurrence in patients with ankylosing spondylitis","volume":"13","author":"Lee","year":"2025","journal-title":"Biomedicines"},{"key":"B45","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1093\/mr\/road039","article-title":"Interferon-alpha 1 expression indicates the disease activity and response of patients with ankylosing spondylitis to anti-TNF-\u03b1 treatment","volume":"34","author":"Li","year":"2024","journal-title":"Mod. Rheumatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e001079","DOI":"10.1136\/rmdopen-2019-001079","article-title":"Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: nordic collaborative observational study of 2334 biologics na\u00efve patients with spondyloarthritis","volume":"5","author":"Lindstr\u00f6m","year":"2019","journal-title":"RMD Open"},{"key":"B47","doi-asserted-by":"publisher","first-page":"6090","DOI":"10.1002\/jcp.30313","article-title":"Osteoimmunological insights into the pathogenesis of ankylosing spondylitis","volume":"236","author":"Liu","year":"2021","journal-title":"J. Cell. Physiology"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1260247","DOI":"10.3389\/fgene.2024.1260247","article-title":"Association of ankylosing spondylitis with cardiovascular disease: a bidirectional two-sample mendelian randomization study","volume":"15","author":"Liu","year":"2024","journal-title":"Front. Genet."},{"key":"B49","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41584-021-00625-y","article-title":"Ankylosing spondylitis: an autoimmune or autoinflammatory disease?","volume":"17","author":"Mauro","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1007\/s10067-021-05588-9","article-title":"Pregnancy outcomes in women with ankylosing spondylitis: a scoping literature and methodological review","volume":"40","author":"Mokbel","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11926-017-0658-4","article-title":"Switching between reference biologics and biosimilars for the treatment of rheumatology, gastroenterology, and dermatology inflammatory conditions: considerations for the clinician","volume":"19","author":"Moots","year":"2017","journal-title":"Curr. Rheumatol. Rep."},{"key":"B52","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13075-016-0930-4","article-title":"Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study","volume":"18","author":"Park","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"B53","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1136\/annrheumdis-2015-208783","article-title":"Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study","volume":"76","author":"Park","year":"2017","journal-title":"Ann. Rheumatic Dis."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e009661","DOI":"10.1136\/bmjopen-2015-009661","article-title":"Biologic treatment registry across Canada (BioTRAC): a multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitis","volume":"6","author":"Rahman","year":"2016","journal-title":"BMJ Open"},{"key":"B55","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann. Rheumatic Dis."},{"key":"B56","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40744-017-0085-z","article-title":"Treatment outcomes with biosimilars: be aware of the nocebo effect","volume":"4","author":"Rezk","year":"2017","journal-title":"Rheumatol. Ther."},{"key":"B57","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s00296-024-05763-6","article-title":"Monitoring disease activity and treatment response in ankylosing spondylitis: a retrospective study of hematologic inflammatory markers","volume":"45","author":"Sadioglu Cagdas","year":"2024","journal-title":"Rheumatol. Int."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s40261-021-01093-8","article-title":"Subcutaneous infliximab, CT-P13 SC: a profile of its use in the EU","volume":"41","author":"Shirley","year":"2021","journal-title":"Clin. Drug Investig."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1102405","DOI":"10.3389\/fimmu.2022.1102405","article-title":"Vesicular traffic-mediated cell-to-cell signaling at the immune synapse in ankylosing spondylitis","volume":"13","author":"Tavasolian","year":"2023","journal-title":"Front. Immunol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/art.40324","article-title":"Subjective complaints as the main reason for biosimilar discontinuation after open\u2010label transition from reference infliximab to biosimilar infliximab","volume":"70","author":"Tweehuysen","year":"2018","journal-title":"Arthritis & Rheumatology"},{"key":"B72","volume-title":"Biosimilar product information","year":""},{"key":"B61","doi-asserted-by":"publisher","first-page":"7266","DOI":"10.3390\/jcm13237266","article-title":"Efficacy and safety of CT-P13 as First- and second-line treatment in patients with ankylosing spondylitis","volume":"13","author":"Uslu","year":"2024","journal-title":"JCM"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1038\/s41588-023-01612-7","article-title":"Immunotherapy for ankylosing spondylitis","volume":"55","author":"Vogan","year":"2023","journal-title":"Nat. Genet."},{"key":"B63","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1080\/1744666X.2020.1748500","article-title":"Placebo responses in ankylosing spondylitis patients worldwide: variations and possible explanations","volume":"16","author":"Wei","year":"2020","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1007\/s11096-019-00859-7","article-title":"Adverse events in patients with ankylosing spondylitis treated with TNF inhibitors: a cross-sectional study","volume":"41","author":"Wro\u0144ski","year":"2019","journal-title":"Int. J. Clin. Pharm."},{"key":"B65","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41413-019-0057-8","article-title":"Ankylosing spondylitis: etiology, pathogenesis, and treatments","volume":"7","author":"Zhu","year":"2019","journal-title":"Bone Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1803260\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:46:51Z","timestamp":1776232011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1803260\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":71,"alternative-id":["10.3389\/fphar.2026.1803260"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1803260","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"article-number":"1803260"}}